研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China,510180[3]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[4]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[5]The First Affiliated Hospital Of Nanchang University,Nanchang,Jiangxi,China,330038[6]Shanghai Pulmonary Hospital,Shanghai,Shanghai,China,200000[7]The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shanxi,China,710004[8]The First Affiliated Hospital of Xi'an Jiao Tong University,Xi'an,Shanxi,China,710061[9]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610040[10]Mianyang Central Hospital,Mianyang,Sichuan,China,621099[11]Yunnan Cancer Hospital,Kunming,Yunnan,China,650118
研究目的：
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers
